Leveraging the genetic and biological bases that contribute to obesity, the MyPhenome swab test identifies patients with the hungry gut phenotype to determine who may respond well to semaglutide. Data were analyzed using the company’s Machine-Learning Gene Risk Score algorithm to determine if patients were hungry gut positive or negative. MyPhenome is poised to address these issues in the obesity space by optimizing the use and distribution of semaglutide. Study demonstrates MyPhenomeTM Hungry Gut test identifies responders to semaglutide. Novo Nordisk’s $1,000 diabetes drug Ozempic can be made for less than $5 a month, study suggests.

Source: Wall Street Journal May 22, 2024 19:25 UTC